Omnicell (OMCL)
NASDAQ:OMCL
Top Page
Omnicell
(NASDAQ:OMCL)
Select Model
Select Model
Rating:54Neutral
Price Target:
$33.00
▼(-6.96% Downside)
Action:ReiteratedDate:02/06/26
The score is held back most by weak technicals (oversold with negative momentum) and very stretched valuation (extremely high P/E with no dividend support). Financially, debt reduction and positive free cash flow help, but thin and volatile profitability remains a key risk. Earnings call guidance is moderately constructive, but tariff-driven margin pressure and recent EPS/cash weakness temper the outlook.
Positive Factors
Stronger balance sheet / lower leverage
Material debt reduction and a large equity base increase financial flexibility to fund R&D, service expansion and discrete M&A without jeopardizing liquidity. Lower leverage also reduces interest burden and improves resilience through hospital capital-cycle variability over the next 2–6 months and beyond.
Negative Factors
Thin, volatile profitability
Very low net margin and a history of swings (loss in 2023, thin profits in 2025) constrain the company’s ability to compound shareholder value. Modest revenue gains must convert into meaningful margin improvement to sustainably fund growth and justify reinvestment over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Stronger balance sheet / lower leverage
Material debt reduction and a large equity base increase financial flexibility to fund R&D, service expansion and discrete M&A without jeopardizing liquidity. Lower leverage also reduces interest burden and improves resilience through hospital capital-cycle variability over the next 2–6 months and beyond.
Read all positive factors
Omnicell (OMCL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.61B
Dividend YieldN/A
Average Volume (3M)561.76K
Price to Earnings (P/E)1014.7
Beta (1Y)0.38
Revenue Growth10.67%
EPS GrowthN/A
CountryUS
Employees3,620
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.40
Shares Outstanding45,435,917
10 Day Avg. Volume390,920
30 Day Avg. Volume561,761
Financial Highlights & Ratios
PEG Ratio-12.16
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit3.22
Enterprise Value/Ebitda17.68
Forecast
1Y Price Target
$57.75Price Target Upside62.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)1.75
Revenue Forecast (FY)$1.24B
Omnicell Business Overview & Revenue Model
Company Description
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to impr...
How the Company Makes Money
Omnicell makes money by selling and supporting a combination of (1) medication management hardware, (2) software, and (3) associated services. A key revenue stream is the sale of automation and dispensing equipment (e.g., automated dispensing cabi...
Omnicell Key Performance Indicators (KPIs)
Any
Gross Profit by Segment
Analyzes profitability across different business segments, highlighting which areas contribute most to the bottom line and where there might be opportunities or challenges.
Analyzes profitability across different business segments, highlighting which areas contribute most to the bottom line and where there might be opportunities or challenges.
Data provided by:
The Fly
The FlyOmnicell Earnings Call Summary
Earnings Call Date:Feb 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call presents a cautiously optimistic outlook: Omnicell reported revenue and ARR growth, exceeded guidance midpoints for bookings and revenue, and launched strategic products (Titan XT, Omnisphere) with encouraging customer response and a stronger pipeline. However, the company faces margin pressure (tariffs and mix), lower GAAP/non-GAAP per-share results in the quarter and year, a meaningful cash balance reduction due to debt repayment and buybacks, and some service/retail segment headwinds. Management frames the adverse items as strategic investments (product launch, financing options, ERP transformation and go-to-market investments) that position the company for multi-year growth and higher recurring revenue, and 2026 guidance reflects modest top-line and EBITDA expansion while factoring in tariff and ERP costs. On balance, the positive operational momentum and guidance modestly outweigh the financial headwinds, but execution on margin recovery and conversion to Titan/Omnisphere will be critical.Positive Updates
Annual Recurring Revenue (ARR) Growth
Exited 2025 with ARR of $636M, up 10% from the 2024 exit rate; 2026 year-end ARR guidance of $680M–$700M (projected ~7%–10% growth vs. 2025 exit).
Negative Updates
Gross Margin Compression
Full-year non-GAAP gross margin declined to 43.2% in 2025 from 47.4% in 2024 (≈ -4.2 percentage points), driven by ~$7M of tariff costs in 2025 and product/customer mix shifts; 2026 tariff P&L impact estimated at ~$15M.
Read all updates
Q4-2025 Updates
Positive
Negative
Annual Recurring Revenue (ARR) Growth
Exited 2025 with ARR of $636M, up 10% from the 2024 exit rate; 2026 year-end ARR guidance of $680M–$700M (projected ~7%–10% growth vs. 2025 exit).
Read all positive updates
Company Guidance
Omnicell guided Q1 2026 total revenue of $300–$310M (product $171–176M; service $129–134M), with Q1 non‑GAAP EBITDA of $27–33M and non‑GAAP EPS of $0.26–0.36 (noting seasonally higher payroll/tax costs). For full‑year 2026 it forecast product bookings of $510–560M, total revenue of $1.215–1.255B (product $690–710M; service $525–545M), year‑end ARR of $680–700M, non‑GAAP EBITDA of $145–160M and non‑GAAP EPS of $1.65–1.85. Management’s guidance incorporates an estimated ~$15M of tariff costs hitting the P&L in 2026, an estimated non‑GAAP effective tax rate of ~13%, and about $10M of ERP implementation costs in 2026, and reflects an expected ~2x EBITDA expansion versus revenue growth while incremental Omnisphere software revenue is expected to materialize beginning in 2027.Omnicell Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
74
Positive
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.18B | 1.11B | 1.15B | 1.30B | 1.13B |
| Gross Profit | 503.44M | 471.00M | 499.93M | 588.99M | 554.65M |
| EBITDA | 96.28M | 90.09M | 79.98M | 96.85M | 174.44M |
| Net Income | 2.05M | 12.53M | -20.37M | 5.65M | 77.85M |
Balance Sheet | |||||
| Total Assets | 1.97B | 2.12B | 2.23B | 2.21B | 2.14B |
| Cash, Cash Equivalents and Short-Term Investments | 196.52M | 381.68M | 467.97M | 341.85M | 359.72M |
| Total Debt | 204.34M | 382.55M | 614.09M | 616.74M | 541.01M |
| Total Liabilities | 742.91M | 877.65M | 1.04B | 1.08B | 995.81M |
| Stockholders Equity | 1.23B | 1.24B | 1.19B | 1.13B | 1.15B |
Cash Flow | |||||
| Free Cash Flow | 86.89M | 151.26M | 139.62M | 17.04M | 202.84M |
| Operating Cash Flow | 127.30M | 187.72M | 181.09M | 77.78M | 231.81M |
| Investing Cash Flow | -60.36M | -52.79M | -55.02M | -58.67M | -412.50M |
| Financing Cash Flow | -218.32M | -235.58M | 23.42M | -20.95M | 47.36M |
Omnicell Technical Analysis
Positive
35.47
Price Trends
38.63
Negative
41.14
Negative
36.04
Negative
Market Momentum
-1.28
Negative
48.46
Neutral
66.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Positive. The current price of 35.47 is above the 20-day moving average (MA) of 34.33, below the 50-day MA of 38.63, and below the 200-day MA of 36.04, indicating a neutral trend. The MACD of -1.28 indicates Negative momentum. The RSI at 48.46 is Neutral, neither overbought nor oversold. The STOCH value of 66.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OMCL.
Omnicell Risk Analysis
Omnicell disclosed 33 risk factors in its most recent earnings report. Omnicell reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Omnicell Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $739.96M | 42.49 | 4.84% | ― | 1.30% | ― | |
61 Neutral | $860.94M | -885.94 | -0.15% | ― | 11.47% | ― | |
55 Neutral | $2.94B | -46.73 | -5.69% | ― | 1.92% | 59.18% | |
54 Neutral | $1.61B | 1,014.72 | 0.17% | ― | 10.67% | ― | |
52 Neutral | $936.58M | -6.16 | -14.24% | ― | -2.37% | 77.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $272.40M | -0.85 | -69.22% | ― | -16.65% | -71.92% |
* Healthcare Sector Average
OMCL
Omnicell
35.47
4.39
14.12%
EVH
Evolent Health
2.44
-7.45
-75.33%
TDOC
Teladoc
5.25
-1.99
-27.49%
TXG
10x Genomics
23.00
15.30
198.70%
GDRX
GoodRx Holdings
2.16
-2.16
-50.00%
CERT
Certara
5.41
-5.10
-48.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.